China Cell Therapy Market Size & Outlook, 2023-2030
China Cell Therapy Market, 2018-2030 (US$M)
Global Market
Related Markets
China cell therapy market highlights
- The China cell therapy market generated a revenue of USD 48.0 million in 2023 and is expected to reach USD 214.8 million by 2030.
- The China market is expected to grow at a CAGR of 23.9% from 2024 to 2030.
- In terms of segment, autologous therapies was the largest revenue generating therapy type in 2023.
- Autologous Therapies is the most lucrative therapy type segment registering the fastest growth during the forecast period.
Cell therapy market data book summary
| Market revenue in 2023 | USD 48.0 million |
| Market revenue in 2030 | USD 214.8 million |
| Growth rate | 23.9% (CAGR from 2023 to 2030) |
| Largest segment | Autologous therapies |
| Fastest growing segment | Autologous Therapies |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Autologous Therapies |
| Key market players worldwide | Novartis AG ADR, Gilead Sciences Inc, Bristol-Myers Squibb Co, Johnson & Johnson, JCR Pharmaceuticals Co Ltd, JW (Cayman) Therapeutics Co Ltd Ordinary Shares, Atara Biotherapeutics Inc, Medipost, Beiersdorf AG, Nkarta Inc Ordinary Shares |
Other key industry trends
- In terms of revenue, China accounted for 1.0% of the global cell therapy market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, South Korea cell therapy market is projected to lead the regional market in terms of revenue in 2030.
- India is the fastest growing regional market in Asia Pacific and is projected to reach USD 103.7 million by 2030.
China cell therapy market is anticipated to witness significant growth over the forecast period due to increasing demand for ATMPs and the rising attention of industry participants on ATMPs. The companies and authorities operating in the country focus on cell & gene therapy.
For instance, in August 2023, China's National Medical Products Administration (NMPA) approved an Investigational New Drug (IND) application for OriCAR-017 from Oricell Therapeutics. This authorized it to study autologous CAR T-cell therapy for patients suffering from advanced multiple myeloma.
Furthermore, players operating in the country are increasing clinical trials for cell therapies targeting various conditions. For instance, in March 2023, JW Therapeutics initiated a phase 2 clinical trial of relmacabtagene autoleucel injection. Thus, such increasing clinical trials and approvals for cell therapies are anticipated to fuel the competition in the cell therapy market in China.
Key Regions:U.S., UK, Japan, South Korea, Germany
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Three ways to get this data
Subscribe to the databook, customize it, or ask a question.Horizon Databook
Unlock every chart on this page and get dashboard access
- Statistics1.2M+ across all markets
- Databooks30K+ global, 120K+ country
- Companies200K+ profiles
- ExportPDF, Dashboard, XLS & PNG, licensed to cite
Customize it
Customize data as per your requirement
- AddCountries, segments, years
- RecutTo your product definition
- ExtendCompany-level detail
- OrA bespoke databook
- Turnaround5–10 working days
Ask Prism AI
A cited answer in seconds
- Corpus30,000 studies, 1.2M points
- ScopeAll markets, not just this
- CitationTraced to report & table
- HonestySays "not covered" if so
- SpeedSeconds, not days
Cell Therapy Market Scope
Cell Therapy Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Johnson & Johnson | View profile | 134,400 | One Johnson and Johnson Plaza, New Brunswick, NJ, United States, 08933 | www.jnj.com |
| Novartis AG ADR | View profile | 76,057 | Lichtstrasse 35, Basel, Switzerland, 4056 | www.novartis.com |
| Bristol-Myers Squibb Co | View profile | 34,100 | Route 206 and Province Line Road, Princeton, New Jersey, NJ, United States, 08543 | www.bms.com |
| Beiersdorf AG | View profile | 21,958 | Unnastrasse 48, Hamburg, Germany, 22529 | www.beiersdorf.com |
| Gilead Sciences Inc | View profile | 18,000 | 333 Lakeside Drive, Foster, CA, United States, 94404 | www.gilead.com |
| JCR Pharmaceuticals Co Ltd | View profile | 932 | 3-19 Kasuga-cho, Ashiya, Hyogo, Japan, 659-0021 | www.jcrpharm.co.jp |
| Medipost | View profile | 51-100 | Seongnam, Kyonggi-do, South Korea, Asia | www.medi-post.com/ |
| JW (Cayman) Therapeutics Co Ltd Ordinary Shares | View profile | 398 | No. 699 Zhong Ke Road, 5F, Building B, Pudong New District, Shanghai, China, People's Republic of | www.jwtherapeutics.com |
| Atara Biotherapeutics Inc | View profile | 173 | 2380 Conejo Spectrum St, Suite 200, Thousand Oaks, CA, United States, 91320 | www.atarabio.com |
| Nkarta Inc Ordinary Shares | View profile | 150 | 1150 Veterans Boulevard, South San Francisco, CA, United States, 94080 | www.nkartatx.com |
China Cell Therapy Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Cell Therapy Market Outlook will help companies and investors design strategic landscapes.
Autologous Therapies was the largest segment with a revenue share of 100.0% in 2023.
Horizon Databook has segmented the China cell therapy market based on autologous therapies covering the revenue growth of each sub-segment from 2018 to 2030.
China cell therapy market is anticipated to witness significant growth over the forecast period due to increasing demand for ATMPs and the rising attention of industry participants on ATMPs. The companies and authorities operating in the country focus on cell & gene therapy.
For instance, in August 2023, China's National Medical Products Administration (NMPA) approved an Investigational New Drug (IND) application for OriCAR-017 from Oricell Therapeutics. This authorized it to study autologous CAR T-cell therapy for patients suffering from advanced multiple myeloma.
Furthermore, players operating in the country are increasing clinical trials for cell therapies targeting various conditions. For instance, in March 2023, JW Therapeutics initiated a phase 2 clinical trial of relmacabtagene autoleucel injection. Thus, such increasing clinical trials and approvals for cell therapies are anticipated to fuel the competition in the cell therapy market in China.
- China Cell Therapy Market Therapy Type Outlook (Revenue, USD Million , 2018-2030)
- Allogeneic Therapies
- Autologous Therapies
- China Cell Therapy Market Therapeutic Area Outlook (Revenue, USD Million , 2018-2030)
- Oncology
- Cardiovascular Disease (CVD)
- Musculoskeletal Disorders
- Dermatology
- Others
Reasons to subscribe to Cell Therapy Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Cell Therapy Market Outlook databook
- Our clientele includes a mix of Cell Therapy Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the China Cell Therapy Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into China Cell Therapy Market Outlook from 2018 to 2030, including revenue numbers, major trends, and company profiles.
China Cell Therapy Market, 2018-2030 (US$M)
China cell therapy market statistics, by therapy type, 2018-2030 (US$M)
